<i>TP53</i>Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck

Poeta, Maria Luana; Manola, Judith; Goldwasser, Meredith A.; Forastiere, Arlene A.; Benoit, Nicole; Califano, Joseph A.; Ridge, John A.; Goodwin, Jarrard; Kenady, Daniel E.; Saunders, John R.; Westra, William H.; Sidransky, David; Koch, Wayne M.

doi:10.1056/nejmoa073770

Cited by 701 publications

(730 citation statements)

References 32 publications

Supporting

Mentioning

687

Contrasting

Unclassified

Order By: Relevance

“…However, there is not necessarily correlation between IHC and SSCP results 45 ; moreover, decrease in survival can vary if the mutation is disruptive or nondisruptive. 44 These controversies may explain differences as a prognostic factor found so far.…”

Section: Tp53mentioning

confidence: 99%

“…TP53 mutations are found in 39-53% of SCCHN tumors and in 56.7% of laryngeal carcinomas. 44,45 P53 mutations have been demonstrated to be related to poor survival in different publications by using microarray technology, 44 immunohistochemistry (IHC) 46 or single-strand conformational polymorphism (SSCP) analysis followed by DNA sequencing. However, there is not necessarily correlation between IHC and SSCP results 45 ; moreover, decrease in survival can vary if the mutation is disruptive or nondisruptive.…”

Section: Tp53mentioning

confidence: 99%

See 1 more Smart Citation

A genetic view of laryngeal cancer heterogeneity

2016

View full text Add to dashboard Cite

During the recent decades significant improvements in the understanding of laryngeal molecular biology allowed a better characterization of the tumor. However, despite increased molecular knowledge and clinical efforts, survival of patients with laryngeal cancer remains the same as 30 years ago. Although this result may not make major conclusions as preservation approaches were not broadly used until the time of database collection, it seems to be clear that there is still window for improvement.

show abstract

Section: Tp53mentioning

confidence: 99%

Section: Tp53mentioning

confidence: 99%

A genetic view of laryngeal cancer heterogeneity

2016

View full text Add to dashboard Cite

show abstract

“…Biomarkers are defined as biological molecules that (1) correlate with the presence or absence of a disease state, (2) are prognostic correlating with a disease course, or (3) predictive of a tumor's response to a specific therapy. Biomarkers should be objective, independent and require validation by clinical testing and patient outcome.…”

Section: Biomarker Characteristicsmentioning

confidence: 99%

“…(Table 1) An early and common genetic event in oral premalignancy includes LOH of 9p21 in dysplasia/ hyperplasia (30%) and carcinoma (70-80%) [1]. p53 mutations begin to occur in severe dysplasia and are associated with decreased survival in invasive carcinomas (50% incidence) [2]. These markers may augment pathologic margin assessment identifying a group of patients at higher risk of local recurrence.…”

Section: Conventional Squamous Carcinoma Premalignancy Progression Modelmentioning

confidence: 99%

Integration of Biomarkers Including Molecular Targeted Therapies in Head and Neck Cancer

Williams

2010

Head and Neck Pathol

View full text Add to dashboard Cite

Head and neck tumors comprise a wide spectrum of heterogeneous neoplasms for which biomarkers are needed to aid in earlier diagnosis, risk assessment and therapy response. The search for biomarkers includes evaluation of tumor tissues and surrogate materials by molecular, genomic and phenotypic means. Ideal biomarkers should be accurate and easy to perform, highly specific, objective, quantitative, and cost effective. Because of the heterogeneity of head and neck tumors, the integration of multiple selected markers in association with the histopathologic features is advocated for risk assessment. For targeted therapy, however, a single key molecule must be identified. Key molecules and pathways for targeted therapy include growth factor receptors, MAPk/ERk pathway, angiogenesis, and epithelial to mesenchymal transition. Over-expression and mutations of genes in these pathways including EGFR, VEGF, HER2, BRAF and RET, contribute to tumorigenesis in head and neck cancers from squamous carcinomas, to salivary adenocarcinomas and thyroid carcinomas, both follicular and c-cell derived. Monoclonal antibodies to the EGFR receptor and oral tyrosine kinase inhibitors are currently being studied in multiple phase II and III clinical trials to determine their efficacy in head and neck cancers and correlative studies for biomarkers are on-going.

show abstract

“…The p53 is one the most frequently studied molecular markers in HNSCC (Van Houten et al, 2002;Waitzberg et al, 2004;Poeta et al, 2007;Jalali et al, 2011). It is the p53 that plays a significant role in pathways that are responsible for maintaining cellular integrity (Bradford et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

An Australian Retrospective Study to Evaluate the Prognostic Role of p53 and eIF4E Cancer Markers in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): Study Protocol

Singh¹,

Jayaraj²,

Baxi³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Complete surgical resection of the primary tumour is a crucial predictive step for head and neck squamous cell carcinoma (HNSCC), because incomplete resection may lead to increase in the recurrence rate. Molecular cancer markers have been investigated as potential predictors of prognosis marker, to identify patients who are at high risk of local recurrence. This retrospective study aimed to determine the prognostic correlation between p53 and eIF4E expression and clinical characteristics, recurrence and overall survival. 1-74 months). The Kaplan-Meier method was used to generate recurrence and survival curves. This is a first retrospective study of Northern Territory patients, including Indigenous and non-Indigenous Australians. Molecular study of surgical margins could help to identify patients with and without clear margins after surgery and help in choice of the most appropriate adjuvant treatment for HNSCC patients.

show abstract

TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck

Abstract: Disruptive TP53 mutations in tumor DNA are associated with reduced survival after surgical treatment of squamous-cell carcinoma of the head and neck.

Cited by 701 publications

References 32 publications

A genetic view of laryngeal cancer heterogeneity

A genetic view of laryngeal cancer heterogeneity

Integration of Biomarkers Including Molecular Targeted Therapies in Head and Neck Cancer

An Australian Retrospective Study to Evaluate the Prognostic Role of p53 and eIF4E Cancer Markers in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC): Study Protocol

Contact Info

Product

Resources

About